Translation of "Maladie au stade préclinique " (French → English) :

Preclinical disease

Preclinical Toxicologic Guidelines - 1981

Definition: A chronic stage in the development of a schizophrenic illness in which there has been a clear progression from an early stage to a later stage characterized by long- term, though not necessarily irreversible, negative symptoms, e.g. psychomotor slowing; underactivity; blunting of affect; passivity and lack of initiative; poverty of quantity or content of speech; poor nonverbal communication by facial expression, eye contact, voice modulation and posture; poor self-care and social performance. | Chronic undifferentiated schizophrenia Restzustand (schizophrenic) Schizophrenic residual state

preclinical diagnosis of a disease of late onset

Chronic kidney disease stage 1

Chronic kidney disease stage 2

Chronic kidney disease stage 4

Only strains of IPN-virus genogroup 5 are known to cause mortality and clinical disease in farmed salmonids in Europe.

The majority of the molecules investigated do not even make it to the stage of testing in humans for a variety of reasons (e.g. that the assumed activity of the molecule or the mechanism of action is not confirmed, or that pre-clinical studies demonstrate that the safety profile is not acceptable).

The majority of the molecules investigated do not even make it to the stage of testing in humans for a variety of reasons (e.g. that the assumed activity of the molecule or the mechanism of action is not confirmed, or that pre-clinical studies demonstrate that the safety profile is not acceptable).

[16] The rare disease topics in the 2012 and 2013 FP7 Health Calls were: 'Support for international rare disease research; Clinical utility of –omics for better diagnosis of rare diseases; Databases, biobanks and clinical ‘bio-informatics’ hub for rare diseases; Preclinical and clinical development of orphan drugs; Observational trials in rare diseases; Best practice and knowledge sharing in clinical management of rare diseases (2012) and Development of imaging technologies for therapeutic interventions in rare diseases; New methodologies for clinical trials for small population groups (2013).